CorVel (NASDAQ:CRVL – Get Free Report) announced its quarterly earnings results on Tuesday. The business services provider reported $0.61 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $248.55 million for the quarter. CorVel had a net margin of 11.23% and a return on equity of 30.15%.
CorVel Stock Performance
Shares of NASDAQ:CRVL opened at $58.82 on Wednesday. CorVel has a 52 week low of $44.83 and a 52 week high of $117.22. The company’s fifty day moving average is $55.29 and its 200-day moving average is $61.89. The company has a market capitalization of $3.01 billion, a PE ratio of 28.83 and a beta of 0.98.
Insider Activity at CorVel
In other news, insider Maxim Shishin sold 2,400 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $54.00, for a total value of $129,600.00. Following the sale, the insider owned 7,050 shares in the company, valued at approximately $380,700. The trade was a 25.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 44.56% of the company’s stock.
Institutional Investors Weigh In On CorVel
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Report on CRVL
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Featured Stories
- Five stocks we like better than CorVel
- Palo Alto Networks Up 70%: Can the Rally Last Into June?
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
